Short Communication

Molecular characterisation of Duffy (FY) red blood cell variants among voluntary blood donors at the National Blood Grouping Testing Laboratory, Kenya

Rachel N. Githiomi1,2*, Kennedy K. Muna4, Suleiman A. Mbaruk2, Christine, K. Yegon3, Evelyn Chege3, Celestino Obiero3, Genghis H. Lopez5, Eileen V. Roulis5, Catherine A. Hyland5 and Robert L. Flower5,6

1Department of Health Policy Research and Innovation, Ministry of Health, Kenya.
2Department of Medical Laboratory Sciences, Medical School, Mount Kenya University, Kenya.
3Tissue and Transplant Authority Kenya (formally Kenya National Blood Transfusion Service), Kenya.
4Department of Medical Laboratory Sciences, School of Pure, Applied and Health Sciences, Murang’a University of Technology, Kenya.
5Research and Development (R&D), Australian Red Cross Lifeblood, Australia.
6ARC Training Centre for Biopharmaceutical Innovation Queensland University of Technology, Australia.

Received 13 August, 2022; Accepted 13 September, 2022

A variant is an alternative nucleotide located at a specific region of a gene. 48 genes encode for human red cell blood group systems. Variants within these genes encode for alleles, which can be highly polymorphic. The blood group gene loci jointly display all types of inherited variants to include single nucleotide variants insertions/deletions and structural variants. In Africa, there is limited information on the red cell variants. The aim of the study was to establish the frequency Duffy red blood cell variants among the donors in Kenya. The study employed next sequencing method, descriptive statistics and results presented in form of a table. The findings show that Duffy system has three variants to include; homozygous for FY*Null GATA regulatory box variant FY*02N.01/FY*02N.01 or Fy(a−b−) found in 93.52% (101/108), while FY*01/FY*02 and FY c.−67T>C predicted Fy(a+b−) or Fy(a−b+) at 3.70% (4/108) while FY*02/FY*02N.01 predicted Fy(a−b+) at 2.78% (3/108). This study recommends an extended research involving large sample size and introduction of extended phenotyping in the identification of FY antigens population.

Key words: Duffy, variant, allele, FY*A, FY*B, molecular, genome, gene.

INTRODUCTION

A variant is an alternative nucleotide located at a specific region within a gene or genome. A gene variant is a permanent change in the DNA sequence that makes up that genome. 48 genes encode for human red cell blood
Table 1. The frequency and association of predicted Duffy phenotypes and variants.

<table>
<thead>
<tr>
<th>System</th>
<th>Genotype</th>
<th>Predicted Phenotype</th>
<th>n</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY (n=108)</td>
<td>FY<em>02N.01 / FY</em>02N.01</td>
<td>FY(a-b-)</td>
<td>101</td>
<td>93.52</td>
</tr>
<tr>
<td>FY (n=108)</td>
<td>FY<em>01/ FY</em>02N.01 OR FY<em>01N.01/ FY</em>02</td>
<td>FY(a+b-) or FY(a+-b+)²</td>
<td>4</td>
<td>3.70</td>
</tr>
<tr>
<td>FY (n=108)</td>
<td>FY<em>02/ FY</em>02N.01</td>
<td>FY(a+b+)</td>
<td>3</td>
<td>2.78</td>
</tr>
</tbody>
</table>

²The GATA mutation on the FY gene. FY c.–67T>C, is more likely to be associated with FY*02 (FY*B) than the FY*01(FY*A) allele. Individuals who are FY*01/ FY*02 and FY c.–67T>C are likely to be FY(a+b–).

Source: Authors

Inclusion criteria

Samples collected in 4 ml ETDA tubes, non-reactive for transfusion transmission infections (TTIs), with no haemolysis.

Exclusion criteria

This includes all samples that failed the required inclusion criteria in preparation for the manual DNA extraction.

RESULTS

The finding shows that Duffy system has three variants which include: homozygous for FY*Null GATA regulatory box variant FY*02N.01/ FY*02N.01 or FY(a–b–) found in 101/108 (93.52%), while FY*01/ FY*02 and FY c.–67T/C predicted FY(a+b–) or FY(a–b+) found in 4/108 (3.70%) and FY*02/ FY*02N.01 predicted FY(a+b+) found in 3/108 (2.78%) as shown in Table 1.

DISCUSSION

The finding of this study analysis revealed that Duffy system has two major variants: FY(a-b-) and FY(a+b-) or FY(a+b+), respectively. Fya and b are highly immunogenic proteins and thus capable of mounting an immunological response that results to alloimmunisation. The formed antibodies are implicated in causing hemolytic transfusion reactions, transplant rejection as well as haemolytic disease of the fetus and the new born if introduced to recipients via transfusion, transplantation and pregnancy. Patients who are identified to be alloimmunized such as those who receive multiple transfusions (SCD, oncology, dialysis, post-partum hemorrhage should be given FY antigen negative blood and organs for safer outcomes.

Comparing the results with other studies in different populations, there are some minor variations that were observed. In South Africa, black population FY(a-b-) 39% while Fya+ Fyb+ was reported to be 2% (Govender et al., 2021). In Saudi Arabia, type FY(a-b-) was identified in 11.11% (Benahadi et al., 2014). In the Brazilian Japanese population, FY study has shown that FY*01/FY*01(Fya+) occurrence was 59.33%, FY*01/FY*02 (Fya+ Fyb+) was

MATERIALS AND METHODS

A total of 108 anonymous left over blood samples collected in EDTA vacutainers were identified, selected and prepared for molecular genotyping. Manual Genomic DNA extraction was accomplished by the use of QIAamp whole blood DNA mini kit (250 51106) as per manufacturer’s instructions (Qiagen Germany). Library preparation was performed using a custom blood grouping enrichment panel (Roulis et al., 2020), and the Illumina DNA prep enrichment protocol as per manufacturer’s instructions (Illumina Inc., San Diego, CA, USA).
In sub-Saharan African people, FY null phenotypes frequency has been shown to be ≥95%. In the Indian population, the FY types indicated that FY (a-b-) was the most common 42.1%, FY (a+b-) most occurring in the white population 49%, and FY (a-b-) most prevalent in the black people 68% (Hovse et al., 2011). Most of those expressing the null phenotypes were from the black population (Makroo et al., 2013). A study conducted by Rodriguez (2020), revealed that most Africans have FY(ab-) that is the FY null phenotype. He also observed that 68% of the African Americans and 88-100% and 90% people of West Africa were Duffy negative FY(ab-). The null FY(ab-) type silences the gene in the erythroid cells. He together with other authors have shown that this null Duffy phenotype is rare in the Caucasians (Rodriguez, 2020).

Conclusion

The study revealed that there are two major variants associated with the Duffy system in the blood donor population: FY*02N.01/FY*02 N.01 97 (89.37%) and FY*01/FY*02N.01OR FY*01N.01/FY*02 11 (10.19%). These variants give rise to two phenotypes or blood types FY null (ab-) erythroid cells only and FY (a+b) or FY (a-b+), respectively. The results from different studies have shown some variations in different population. However, despite of the differences, the null phenotypes FY (a-b-) is the most common in the African population.

RECOMMENDATION

The study employed molecular genotyping (NGS) to determine the presence of the red cell variants in the blood donor population. In addition to confirmed presence of red cell variants, valuable knowledge is presented on the basis for improved investigations of the red cell variants in the Kenya. This study outcome is very beneficial in resolving cases associated with adverse transfusion reaction especially in ongoing and massively transfused patients (Sickle cells, cancer cases among others) matching and as variants reference gene bank in Kenya. The results of this study in combination with others related to other blood groups red cell variants will be useful in instituting a blood grouping molecular reference laboratory for Kenya and East Africa community. It will also be useful evidence to consider use of extended phenotyping in blood bank laboratories both in Kenya and East Africa in the identification of rare phenotypes that are of clinical significance in transfusion medicine. More research on this field in Kenya and East Africa will enrich the gene data base and strengthen the blood grouping laboratories in the investigations of complicated complex cases as well as enhance collaborations nationally and internationally.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

ACKNOWLEDGEMENT

The authors thank the Ministry of Health-Kenia, Tissue and Transplant Authority Kenya (formally Kenya National Blood Transfusion Service), Mount Kenya University, Queensland University of Technology Australia & Development, Clinical Services and Research, and Australian Red Cross Blood Service.

ABBREVIATIONS

EDTA, Ethylenediaminetetraacetic acid; HDFN, haemolytic disease of the fetus and the new born; HTR, haemolytic transfusion reaction; KNBTS, Kenya National Blood Transfusion Service; RBCs, red blood cells; SNVs, single nucleotide variants.

REFERENCES


